Group One Trading Adds $883K in AbCellera Biologics Inc. ($ABCL)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Group One Trading increased its position in AbCellera Biologics Inc. ($ABCL) by 85.38% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 239,133 shares of AbCellera Biologics Inc. after buying 110,134 shares during the quarter. Group One Trading's holdings in AbCellera Biologics Inc. were worth $1.92 million as of its most recent filing.
AbCellera Biologics Inc. Stock Down 29.4%
Shares of AbCellera Biologics Inc. ($ABCL) traded around $8.02 on Saturday, down 29.4% for the day.
AbCellera Biologics Inc. Earnings
Analysts Set New Price Targets
About AbCellera Biologics Inc.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Get AbCellera Biologics Inc. alerts
New 13F filings, insider trades, and analyst moves on $ABCL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.